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Enzymatic utilization of nicotinamide adenine dinu-
cleotide (NAD) has increasingly been shown to have
fundamental roles in gene regulation, signal trans-
duction, and protein modification. Many of the pro-
cesses require the cleavage of the nicotinamide moi-
ety from the substrate and the formation of a reactive
intermediate. Using X-ray crystallography, we show
that human CD38, an NAD-utilizing enzyme, is capa-
ble of catalyzing the cleavage reactions through both
covalent and noncovalent intermediates, depending
on the substrate used. The covalent intermediate is
resistant to further attack by nucleophiles, resulting
in mechanism-based enzyme inactivation. The non-
covalent intermediate is stabilized mainly through
H-bond interactions, but appears to remain reactive.
Our structural results favor the proposal of a non-
covalent intermediate during normal enzymatic utili-
zation of NAD by human CD38 and provide structural
insights into the design of covalent and noncovalent
inhibitors targeting NAD-utilization pathways.
INTRODUCTION
Nicotinamide adenine dinucleotide (NAD) is widely known to be
a ubiquitous coenzyme of oxidation-reduction reactions in cells.
Accumulating evidence indicates, however, that it can function
not only as a coenzyme itself, but can also serve as a substrate
for multiple enzymes called NAD-utilizing enzymes. The latter
processes generally involve the enzymatic removal of its nico-
tinamide (Nic) moiety by specific NAD-utilizing enzymes. The re-
maining adenine diphosphate (ADP)-ribosyl portion then forms
a reactive intermediate with the catalyzing enzyme, which can
be further used for multiple processes, depending on the en-
zyme, such as protein ADP-ribosylation by some bacteria toxins
(O’Neal et al., 2005) and mono-ADP-ribosyl transferases
(Seman et al., 2004), histone deacetylation by sirtuin family pro-
teins (Blander and Guarente, 2004; Sauve and Schramm, 2004),
and the biosynthesis of the calcium mobilization messengers
cyclic ADP-ribose (cADPR) and ADP-ribose (ADPR) by ADP-
ribosyl cyclases (Guse, 2005; Howard et al., 1993; Lee, 2001).1068 Chemistry & Biology 15, 1068–1078, October 20, 2008 ª2008These processes are known to have important cellular and
physiological functions in DNA repair (Lombard et al., 2005;
Michan and Sinclair, 2007), transcriptional regulation (Blander
and Guarente, 2004), cellular differentiation and proliferation,
aging (Hassa et al., 2006), and calcium signaling (Lee, 2001;
Lee et al., 1999).
Although NAD is a substrate for multiple enzymes, the initial
steps of the cleavage and release of the nicotinamide moiety
are conserved. The nature of the subsequent intermediates
formed, on the other hand, has been a widely debatable issue.
Both covalent and noncovalent intermediates have been pro-
posed (Figure 1A). In the former case, after the cleavage and
the release of the nicotinamide, the remaining ribonucleotide
forms a covalent bond with the catalytic residue (Sauve et al.,
2000; Sauve and Schramm, 2002; Smith and Denu, 2006). In
the noncovalent intermediate, it is proposed to be an oxocarbe-
nium ion intermediate stabilized by noncovalent interactions
(Berti et al., 1997; Handlon et al., 1994; Oppenheimer, 1994;
Schuber and Lund, 2004; Tarnus et al., 1988; Tarnus and
Schuber, 1987). As the characteristics of the intermediate deter-
mine the catalytic outcome of NAD utilization and are crucial for
design of potent inhibitors for pharmacological purposes, it is im-
portant to characterize the chemical and structural nature of the
intermediates.
In this study, we investigate the intermediates of CD38, a mul-
tifunctional protein that is not only a lymphocyte antigen, but also
an NAD-utilizing enzyme. As amember of NAD-utilizing enzymes
of the ADP-ribosyl cyclase family (EC 3.2.2.5), human CD38 is
a type-II transmembrane ectoenzyme that catalyzes the conver-
sions of NAD to cADPR and ADPR (Figure 1B) (Howard et al.,
1993; Lee, 1994; Lee et al., 1989, 1993). Both products are cal-
cium messenger molecules targeting different calcium channels
and stores (reviewed by Lee [2001, 2004]). It has been proposed
that, after the release of the nicotinamide moiety, the intermedi-
ate shown in Figure 1A can either be attacked intramolecularly
(by the N1 atom of the adenine terminus) to form cADPR, or in-
termolecularly (by a water molecule) to form ADPR, respectively
(reviewed by Lee [2000, 2006]). In this study, we employed X-ray
crystallography to investigate the nature of the intermediates
formed during the catalysis of CD38. The results show that
both covalent and noncovalent intermediates can be formed, de-
pending on the substrates. The structural results provide direct
evidence for the pivotal role of the intermediate in determining
subsequent reaction steps.Elsevier Ltd All rights reserved
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Covalent Intermediate
Nicotinamide mononucleotide (NMN) is a truncated version of
the substrate NAD (Figure 1A), and can be hydrolyzed by CD38
to form ribose-50-phosphate (R5P) (Sauve et al., 1998). We fo-
cused on this alternative reaction because the reaction interme-
diate should be structurally simpler without the adenine terminus
of NAD. An NMN analog, arabinosyl-20-fluoro-20-deoxynicotina-
mide mononucleotide (ara-F-NMN), was used, which has a fluo-
rine atom (20-fluoro) substituting for the 20-OH group in the trans
orientation (Figure 2A). We show in Figure 2B that a covalent in-
termediate was formed after the release of the nicotinamidemoi-
ety. The covalent ara-F-R5P/wtCD38 complex was obtained by
cocrystallization, and its structure was determined by X-ray crys-
tallography at 2.0 A˚ resolution. The structure shows that the cat-
alytic residue Glu226 forms a covalent acylal ester bond with the
ara-F-R5P (Figure 2C). The covalent bond length is 1.6 A˚, linking
Figure 1. Schematic Diagram of the Reac-
tions of NAD Catalysis
(A) Nicotinamide cleavage results in the forma-
tion of possible covalent and noncovalent
intermediates.
(B) Reactions of forming cADPR or ADPR from
NAD catalyzed by CD38.
the carboxylate oxygen of Glu226 to the
C10 carbon of the ara-F-R5P. Aside from
the covalent linkage, there are additional
hydrogen-bonding interactions between
the enzyme and the phosphate group of
ara-F-R5P, contributing to further stabili-
zation of the covalent intermediate
(Figure 2C). Another indication of the sta-
bility of the covalent intermediate is the
observation that there are four water mol-
ecules trapped in the active site that are
close to the intermediate (Figure 2C).
These water molecules have H-bond in-
teractions with protein residues Glu146,
Asp155, as well as with the intermediate,
ara-F-R5P. Nevertheless, these bound
water molecules are not sufficient to pro-
mote the hydrolysis of the covalent inter-
mediate to ara-F-ADP-ribose. The under-
lying reason is indicated by a close
inspection of the conformation of the ara-
binosyl ring. The ring plane is seen to be
almost parallel to the covalent bond, re-
sulting in the covalent bond being
shielded in a hydrophobic environment
formed by residue Thr221. As a result,
none of these four water molecules lies
in a position suitable for nucleophilic at-
tack of the covalent bond from the
b face of the ring. These structural fea-
tures of thecovalent intermediate indicate
that it is highly stable and, once formed, prevents further catalysis
by CD38, which is consistent with ara-F-NMN being a mecha-
nism-based inhibitor, with a Ki of 61 nM (Sauve et al., 2000).
Dynamics of the Covalent Intermediate
Despite its high potency, the inhibitory effect of ara-F-NMN,
however, can be reversed in the presence of high concentrations
of nicotinamide (Sauve et al., 2000). Based on the covalent inter-
mediate structure described above, we reasoned that, to re-
cover the enzyme’s activity, the arabinosyl ring of the intermedi-
ate should be able to adopt an alternative orientation so that its
C10 atom is accessible to a nucleophile, such as nicotinamide.
That is, the arabinosyl ring itself should be dynamic and able to
reposition itself upon the approach of a strong nucleophile.
Although water is a good nucleophile in producing R5P from
substrate NMN during its hydrolysis by CD38 (Sauve et al.,
1998), it is not capable of doing so with ara-F-NMN as substrate
(Figure 2C). Instead, the inhibition reversal by nicotinamideChemistry & Biology 15, 1068–1078, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1069
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probe the possible dynamic behavior of the covalent intermedi-
ate. We introduced nicotinamide into the active site by soaking
wild-type CD38 (wtCD38) crystals with 15 mM ara-F-NMN and
50 mM nicotinamide at 4C. The tertiary complex (ara-F-R5P/
Nic/wtCD38) was obtained and the electron density defines
clearly the entity of a nicotinamide together with the covalent in-
termediate in the active site (Figure 3A). The tertiary complex
shows that nicotinamide is positioned and stabilized by both hy-
drophilic interactions with residues Glu146 and Asp155, as well
as hydrophobic interactions with Trp189 through ring-ring stack-
ing. These three residues have previously been identified to form
a recognition site for the nicotinamide moiety of substrate NAD
(or nicotinamide guanine dinucleotide [NGD]), the adenine group
of cADPR, and the guanine group of cGDPR (Liu et al., 2006,
2007). In the current complex, nicotinamide is on the b face of
the ara-F-R5P intermediate and is 3.7 A˚ away from the C10 car-
bon (Figure 3A), too far to elicit an efficient nucleophilic attack of
the covalent intermediate. Nevertheless, the bound nicotinamide
does interact strongly with the intermediate, as shown in
Figure 3B, where the covalent intermediates with and without
nicotinamide are superimposed. It can be clearly seen that the
binding of nicotinamide at the active site completely evacuates
the water molecules seen in the nicotinamide-free covalent inter-
Figure 2. Covalent Intermediate after the
Cleavage of Nicotinamide
(A) Chemically synthesized ara-F-NMN, a mecha-
nism-based analog of substrate NMN.
(B) Overall structure of CD38 with its catalytic res-
idue Glu226 covalently linked to ara-F-R5P. The
two domains of CD38 are differently colored to
show that the intermediate is in the gulf between
two domains. The covalent linkage is shown as
sticks.
(C) A stereo presentation of active-site structure
showing the trapping of intermediate species
ara-F-R5P. The 2Fo  Fc omit electron densities
(with ara-F-R5P omitted during the calculation of
the electron density map) for the trapped covalent
intermediate is shown as gray isomesh at 1.0 s.
The active-site residues are shown as sticks with
their carbon atoms in gray. Ara-F-R5P, the remain-
ing moiety after the release of leaving group nico-
tinamide from substrate, is also shown as sticks,
but with their carbon atoms in green. The covalent
bond length between Glu226 and ara-F-R5P is
1.6 A˚. Polar interactions between protein and
ara-F-R5P are drawn as cyan dashed lines. Four
water molecules observed in the active site are
shown as red spheres.
mediate. Additionally, the recruitment of
nicotinamide to its binding site appears
to drive the rotation of the arabinosyl
ring of the covalent intermediate from
the nicotinamide-free position (marine
carbon) to the nicotinamide-bound posi-
tion (green carbon). The large nicotin-
amide-induced rotational movement of
the arabinosyl ring suggests that the co-
valent ara-F-R5P intermediate is structurally unstable, even
though it is chemically resistant to hydrolysis. The strong interac-
tion between nicotinamide and the covalent intermediate
suggested by the structures are thus consistent with the bio-
chemical evidence indicating that high concentrations of nicotin-
amide can rescue CD38, although to a limited degree, after its
inhibition by ara-F-NMN (Sauve et al., 2000).
Noncovalent Intermediate
Different fromara-F-NMN,NMN isnot an inhibitor ofCD38,but an
efficient substrate that is hydrolyzed to nicotinamide and R5P
quickly with a KM of 149 mM and a Kcat of 512 s
1 (Sauve et al.,
1998). These kinetic parameters are not in linewith a stable cova-
lent intermediate being formed from NMN, but suggest the pos-
sibility of a labile noncovalent intermediate instead. To trap this
intermediate, we used a guanine-containing molecule. We have
previously shown that the guanine ring of NGD can bind to the
nicotinamide recognition site within the active site of CD38 and
stabilize a noncovalent intermediate formed from the substrate’s
NGD (Liu et al., 2006). The binding of the guanine ring at the nic-
otinamide binding site appears to block entry of water into the
active site and thus prevent the hydrolysis of the noncovalent
intermediate, extending its lifetime for crystallographic study.
Without intermediate trapping, we found that NMN was readily1070 Chemistry & Biology 15, 1068–1078, October 20, 2008 ª2008 Elsevier Ltd All rights reserved
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amide could be detected in the active site (data not shown).
Here we used a heterogenic GTPmolecule to trap the interme-
diate from NMN. We first determined the GTP/CD38 complex
without NMN, as shown in Figure 4A. The complex was formed
by soaking wtCD38 crystals with GTP. As expected, the guanine
ring of GTP occupies the nicotinamide recognition site defined
by residues Glu146, Asp155, and Trp189, and forms extensive
H bonds with Glu146, Asp155, and Thr221. The electron densi-
ties are unambiguous for the guanine ring and the adjacent ri-
bose, but are poor for the remaining part of GTP, as it is out of
the active site and is disordered.
To obtain the noncovalent intermediate, we soaked wtCD38
crystals in a solution of NMN and GTP at 4C for a short period
(less than 3min), followed by flash freezing soaked crystals in liq-
uid nitrogen. This procedure allowed sufficient accumulation of
the reaction intermediate species at the active sites. The corre-
sponding crystal structure determined at 1.73 A˚ shows two
CD38 molecules in the crystallographic asymmetric unit, and
the captured reaction species are shown in Figures 4B and 4C.
In the active site of one molecule, we observed the electron den-
sities corresponding to a GTP in the nicotinamide binding site
(Figure 4B), as well as that corresponding to the R5P intermedi-
ate (R5PI) formed after the cleavage and release of nicotinamide.
Different from the electron density observed for the covalent
Figure 3. DynamicsofCovalent Intermediate
(A) Structure of ara-F-R5P/Nic complex. With the
preexistence of covalent ara-F-R5P intermediate
in the active site, nicotinamide, at high concentra-
tion, can bind to the active site through polar inter-
actions to Glu146 and Asp155, and hydrophobic
stacking interactions to Trp189. The 2Fo  Fc
omit density covering ara-F-R5P and Glu226 is
shown as gray isomesh contoured at 1.0 s; the
Fo  Fc electron density covering nicotinamide is
show as purple isomesh contoured at 2.5 s. Nico-
tinamide is 3.7 A˚ away to the reaction center atom
C10.
(B) Structural comparison of two covalent interme-
diates, with and without nicotinamide, to show the
rearrangement of the covalent intermediate. Inter-
mediate without nicotinamide (marine carbon
atoms) was superimposed on intermediate (green
carbon atoms) with the disturbance of a high
concentration of nicotinamide. Upon the binding
of nicotinamide, the covalent ara-F-R5P intermedi-
ate dynamically rotates its arabinosyl ring 90
around a free phosphate-sugar bond. Accordingly,
four water molecules (marine spheres) are
evacuated from the active site by this rotational
movement.
ara-F-R5P intermediate (Figures 2C or
3A), there is no electron density between
the R5PI and Glu226 (Figure 4B), indicat-
ing that the ribosyl C10 atom does not
form covalent linkage to Glu226, but is in-
stead at a distance of 3.5 A˚ from the cat-
alytic residue Glu226. Moreover, the
carboxylate group of Glu226 forms two H bonds with the ribosyl
20-, 30-OH groups of the noncovalent intermediate (Figure 4B)
that are absent in the covalent intermediate. It is clear that the in-
termediate formed with NMN is structurally distinct from the co-
valent intermediate formed with ara-F-NNM described above.
This intermediate is, on the other hand, very similar to the non-
covalent intermediate formed with NGD that we reported previ-
ously (Liu et al., 2006).
Noncovalent Intermediate Is Reactive
In the active site of the other CD38 molecule in the crystallo-
graphic asymmetric unit, we observed a reaction adduct, R5P-
GTP (Figure 4C), apparently formed by the nucleophilic attack
of the R5PI (Figure 4B) by the guanine O6 of a bound GTP. The
attack is from the b face of the ribose, demonstrating a retaining
feature of the catalysis by CD38. The bond distance between
C10-O6 is 1.9 A˚, longer than the bond distance of a standard
C-O bond (1.33 A˚), suggestive of a dissociative character of
the reaction adduct. That the product R5P-GTP can be formed
indicates that the noncovalent intermediate R5PI, shown in
Figure 4B, is highly susceptible to further attack, even in its crys-
talline state, by any nucleophile nearby, be it the bound GTP
(Figure 4C) or bound water (Figure 2C). This is consistent with
the kinetic data showing that NMN hydrolysis catalyzed by
CD38 is at a high rate, with a Kcat of 512 s
1 (Sauve et al., 1998).Chemistry & Biology 15, 1068–1078, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1071
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(A) The GTP complex. GTP alone can inhibit CD38 by occupying the nicotin-
amide binding site defined by residues Glu146, Asp155, and Trp189. The
Fo  Fc omit (with GTP omitted from the calculation of the electron density
map) electron density is shown as gray isomesh contoured at 2.5 s covering
GTP.
(B) The noncovalent R5PI intermediate trapped by GTP. The noncovalent R5P
intermediate (R5PI) is shown as sticks with its carbon green. R5PI forms two
hydrogen bonds with the catalytic residues Glu226 and Trp125 main chain1072 Chemistry & Biology 15, 1068–1078, October 20, 2008 ª2008Figure 4D aligns and compares the structural features of the
noncovalent (R5PI) and covalent intermediates (ara-F-R5P/
Nic). In ara-F-R5P/Nic, the arabinosyl ring of the ara-F-ribose
apparently moved toward Glu226 to form the covalent linkage.
In the noncovalent intermediate, the ribose forms two H bonds
with the carboxylate group of the catalytic residue Glu226. The
superimposition of the structures of the two intermediates indi-
cates that the N1 atom of the bound nicotinamide (in ara-F-R5P/
Nic complex) is only 2.4 A˚ to the C10 carbon of the R5PI interme-
diate. The close proximity provides structural evidence that R5PI
is likely to be susceptible to nucleophilic attack by nicotinamide.
Indeed, when we soaked CD38 crystals in an NMN solution sup-
plemented with a high concentration of nicotinamide (up to
200 mM), we could not observe any electron densities for either
R5PI or nicotinamide in the active site. This is also consistent with
nicotinamide being an efficient nucleophile in the base-exchange
reaction catalyzed by CD38, with a KM of 0.92 mM and a kcat of
0.007 s1 (Aarhus et al., 1995; Sauve and Schramm, 2002).
Based on the above structural analyses of the covalent and
noncovalent intermediates, we can conclude that the reaction in-
termediate formed during the hydrolysis of regular substrates,
such as NMN, NAD, or NGD, is more reasonably noncovalent.
Covalent intermediate can be, and is, formed, but only with spe-
cial substrate/inhibitor, such as ara-F-NMN.
The NMN/CD38 Complexes
To better understand the catalysis process, we also determined
the Michaelis complex of the substrate NMN. Two different ap-
proaches were used to obtain NMN/CD38 complexes. The first
one was to use a catalytically inactive mutant of CD38 (Munshi
et al., 2000). We have shown that CD38 can be inactivated by
mutating the catalytic residue Glu226 to Gln226, which should
allow the binding of NMN to the active site without being cleaved,
as we have previously done to obtain the Michaelis complexes
with NAD and cADPR (Liu et al., 2006, 2007). Figure 5A shows
that, in the NMN/E226Q complex, the nicotinamide moiety of
NMN binds to the site defined by residues Glu146, Asp155,
and Trp189, the same site for the binding of nicotinamide in
ara-F-R5P/Nic complex. The ribosyl 30-OH group forms one H
bond with the carbonyl group of Gln226. The phosphate group
has an almost identical interaction pattern, as observed in the
R5PI complex (Figures 4B and 5A).
The second approach to obtain the NMN/CD38 complex is to
use the trapping technique described above. We screened
nitrogen. The Fo  Fc omit electron density is shown as gray isomesh con-
toured at 2.8 s. The GTP molecule in the active site (yellow sticks) has almost
the same conformation as in the GTP complex shown in (A). The phosphate
group of R5PI forms extensive H bonds to residues Ser126, Arg127,
Phe222, and Thr221.
(C) A R5P-GTP adduct in which R5PI is attacked by GTP from the b face to
form a covalent bond. The bond distance between C10 and GTP O6 is 1.9 A˚.
The Fo Fc omit electron density (with R5P-GTP omitted from the calculation
of the electron density map) is shown as gray isomesh and contoured at 2.8 s.
(D) Structural comparison of covalent and noncovalent intermediates. The
covalent intermediate (green carbon sticks) with nicotinamide trapped in the
active site is used for the superimposition with R5PI intermediate (gray carbon
sticks). Essential active site residues Glu146, Asp155, Trp189, and Ser193
align quite well, whereas the catalytic residue Glu226 rotates its carboxylate
group by 30 in order to form a covalent intermediate with ara-F-R5P.Elsevier Ltd All rights reserved
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guanosine, and guanine, for their ability to trap NMN in the active
site, by cosoaking each of themwith NMN at low temperature for
a short period.We found that the incubation of 5mMguanine and
40 mM NMN with wtCD38 crystals followed by flash freezing to
liquid nitrogen temperature can accumulate sufficient amounts
of the activated substrates in the active sites for the structural
detection. The solved NMN/wtCD38 complex is shown in
Figure 5B. In contrast to the NMN/E226Q complex (Figure 5A),
the carboxylate group of Glu226 forms two H bonds with the ri-
bose. It is thus clear that the replacement of the carboxylate
group in Glu226 with the corresponding amide results in the
20-OH group of substrate NMN being at a distance of 4.4 A˚
away from the N32 atom of Gln226—too distant to form a hydro-
gen bond. These structural features are remarkably similar to
those seen in the NAD/E226Q complex that we reported previ-
ously (Liu et al., 2006, 2007), and further buttress the proposal
thatweadvancedpreviously, that thedistortionof ribose imposed
by the two H bonds between Glu226 and the riboseOH groups
is critically important for the catalytic activities of CD38.
Role of Substrate Distortion in N-Glycosidic Bond
Cleavage
The role of substrate distortion is further demonstrated in
Figure 5C by aligning and comparing the ara-F-R5P/Nic and
the NMN/wtCD38 complexes, both containing nicotinamide in
Figure 5. Structural Determinants for Nico-
tinamide-Glycosidic Bond Cleavage
(A) NMN/E226Q complex. Substrate NMN is
shown as sticks with its carbon atoms green.
The Fo Fc omit electron density (with NMN omit-
ted from the calculation of the map) is shown as
gray isomesh contoured at 2.5 s. The nicotin-
amide moiety of NMN is recognized by its interac-
tions with Glu146, Asp155, and Trp189. Dashed
lines colored cyan show the specific polar interac-
tions between NMN and the enzyme.
(B) NMN/wtCD38 complex. The presentation
scheme is the same as in (A).
(C) Stereo representation of the structural compar-
ison of the NMN/wtCD38 complex with the ara-F-
R5P/nicotinamide complex. Both complexes are
shown as sticks with green carbon for the NMN/
wtCD38 complex and gray/magenta/yellow
carbon for the ara-F-R5P/nicotinamide/wtCD38
tertiary complex. The alignment of both structures
shows the structural determinants for the enzy-
matic cleavage of nicotinamide.
its free and uncleaved forms (part of
NMN), respectively. In the aligned struc-
tures, both the free nicotinamide and the
uncleaved nicotinamide have polar inter-
actions with residues Glu146 and
Asp155, as well as nonpolar interactions
with residue Trp189. There is, however,
one notable structural difference; namely,
the free nicotinamide ring plane has a 16
rotation relative to the uncleaved nicotinamide ring plane of NMN
(Figure 5C). The relative orientation of the two nicotinamide rings
indicates that, in the Michaelis complex, the substrate NMN is
distorted, and its leaving group can be subjected to a force
that preferentially drives the nicotinamide ring to swing away
from the C10 carbon, displaying a dissociative character of the
nicotinamide-glycosidic bond. The dissociative force includes
hydrophobic interactions and aromatic stacking of the nicotin-
amide ring and the Trp189 indole ring, which has also been pro-
posed to explain N-glycosidic bond cleavage in nucleosides
(Versees et al., 2004).
Additionally, as described above, the H bonds between the
ribosyl 20-OH and Glu226 flattens the ribose ring, absorbing
the electron migration from the nicotinamide-glycosidic bond,
and further destabilizing the substrate, effecting the cleavage
of the nicotinamide-glycosidic bond. After cleavage, the R5P in-
termediate is stabilized by two H bonds between the 20-, 30-OH
groups and the catalytic residue (Figure 4B). The scenario de-
scribed above is fundamentally different from the general belief
that the glycosidic bond cleavage is via direct attack of the ribo-
syl C10 by the catalytic residue. Substrate distortion and leaving
group activation in NMN hydrolysis as the main driving forces for
catalysis are also in accordance with the apparent absence of an
appropriate general acid in the active site of CD38 that is capable
of protonating the leaving group after the cleavage step, as
would be required by a Schiff-acid catalysis mechanism.Chemistry & Biology 15, 1068–1078, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1073
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The nature of the intermediate formed after nicotinamide-glyco-
sidic bond cleavage is a highly debated topic. The two prevailing
models of the intermediate are covalent and noncovalent, as
shown in Figure 1A. We employ the direct approach of X-ray
crystallography to resolve the issue. Using a model substrate
NMN and its analog, ara-F-NMN, we determined the structures
of both types of intermediates, as well as the substrate Michaelis
complexes at high resolution. The results advance our under-
standing of the catalytic mechanism of CD38 and provide sub-
stantial structural clues for the design of potential inhibitors for
pharmacological purposes.
In the ara-F-R5P complex, the replacement of the 20-OH of
NMN with the 20-fluro group apparently reduces the strength of
the interaction between the carboxylate group of Glu226 and
the arabinosyl ring, allowing relative movement of the arabinosyl
ring toward Glu226 to form a covalent linkage. It may very well be
that, after the dissociation of the nicotinamide from ara-F-NMN,
the intermediate is initially noncovalent in nature. However, with-
out the stabilization from the 20-OH via H bonding, the carboxyl-
ate group of Glu226 can rotate and attack the labile C10 atom to
form the covalently linked intermediate (Figure 5C). To do this,
the side chain of Glu226 needs to rotate about 30 tomake a link-
age with the C10 atom of ara-F-ribose. The ara-F-ribose is seen
to move deeper toward Glu226, facilitating the linkage (Fig-
ure 5C). Indeed, the arabinosyl ring of the covalent ara-F-R5P in-
termediate (nicotinamide-free form) is rotated as much as 90
during its movement after the nicotinamide-glycosidic bond
cleavage (Figure 3B). It is entirely possible that the substitution
of the 20-OH group by 20-fluro from the b face of the ara-F-
NMN renders the molecule incapable of forming any H bond
with Glu226, disfavoring the stabilization of the initial noncova-
lent intermediate and promoting the formation of a more stable
covalent intermediate instead. Clearly, once the covalent inter-
mediate is formed, its stability disfavors further catalysis to
occur, and the enzyme is inhibited. Therefore, when NMN is
used as substrate, the intermediate is noncovalent, and its hy-
drolysis rate is high, with a kcat of 512 s
1 (Sauve et al., 1998),
while, with ara-F-NMN, the intermediate is covalent and stable,
and the enzyme is inhibited. Only in the presence of high concen-
trations of nicotinamide can the inhibition be reversed via a base
exchange reaction, which has ameasured KM value of 17mM for
nicotinamide (Sauve et al., 2000). Further evidence supporting
our conclusion is from mutagenesis. The catalytically inactive
E226Q mutant (Munshi et al., 2000), lacking the carboxylate
group of Glu226, is not capable of forming a covalent intermedi-
ate. We indeed found that E226Q could not even bind ara-F-
NMN (i.e., could not form an E226Q/ara-F-NMN complex)
when applying the same soaking protocol used for obtaining
the E226Q/NMN complex (data not shown). We thus propose
that, under normal conditions with the substrates NAD or
NMN, the noncovalent intermediate shown in Figure 4B is both
structurally and kinetically reasonable. This is also supported
by biochemical data (Cakir-Kiefer et al., 2000). Our structural
data strongly support the concept that the same enzyme can
catalyze the nicotinamide-glycosidic bond cleavage through
two entirely different reaction pathways, depending on the sub-
strate involved. The critical structural determinant on the sub-1074 Chemistry & Biology 15, 1068–1078, October 20, 2008 ª2008 Estrate for selecting the catalytic pathways appears to be the
20-OH, as that is the only difference between ara-F-NMN and
NMN.
Structures presented in this study provide clues about why the
20-OH is critical, and point to the importance of H bonding to both
ribosyl OH groups during catalysis. In the R5PI complex, two ri-
bose hydroxyl groups form two H bonds with the catalytic resi-
due Glu226. With this ribose configuration, the intermediate is
noncovalent and is stabilized by the two H bonds (Figure 4B).
The extra H bond with the 20-OH group can sufficiently reduce
the electronegativity of O32 of Glu226, rendering it incapable of
forming a covalent bond with C10. Consequently, the reaction
proceeds through the noncovalent mechanism. The positioning
of the noncovalent intermediate at the active site automatically
allows efficient attack by a nucleophile from its b face, as shown
in Figure 4C. In the ara-F-R5P or ara-F-R5P/Nic complex, there
is no H bond between Glu226 and the 20 position of the arabino-
syl ring. Therefore, the O32 of the Glu226 is free to attack C10 car-
bon and form a covalent bond. This covalent linking processmay
be accelerated by the dynamic rotational movement of the ara-
binosyl ring, as shown in Figure 2B. Likewise, Glu226 also ro-
tates to facilitate the covalent bond formation (Figure 5C).
The chemistry of the intermediate for NAD hydrolysis has been
favored to be an oxocarbenium ion based on independent re-
sults from kinetic isotope effects (Berti et al., 1997; Bull et al.,
1978), catalysis of NAD pyridinium analogs (Tarnus and Schuber,
1987), 20 substitutions effects of NAD ribose (Handlon et al.,
1994), and preferential methanolysis over hydrolysis (Muller-
Steffner et al., 1996). In our study, structural evidence is provided
for a noncovalent intermediate. We were able to apparently trap
the intermediate in the active site by using a GTP molecule to
block the entry of water. This noncovalent intermediate could
be the proposed oxocarbenium ion, although our structural re-
sults do not definitively prove that. We clearly observed that
the intermediate is likely to be formed via interactions between
Glu226 and hydroxyl groups of the ribose. This is consistent
with the mechanism proposed by Oppenheimer, (1994) for the
inductive stabilization of the oxocarbenium ion intermediate via
an interaction between the 20-hydoxyl and an active-site carbox-
ylate. We would thus generalize and propose that for the ribosyl
substrates, such as NMN, NAD, NGD, and nicotinamide ribose,
the enzyme would take the noncovalent oxocarbenium ion
pathway, while, for arabinosyl substrates/analogs, such as
ara-F-NMN, ara-F-NAD, ara-NAD, and 20-deoxy-nicotinamide
ribose, the enzyme would take the covalent reaction pathway.
The structural results in this study provide clues for the ratio-
nal design of efficient covalent and noncovalent inhibitors of
CD38 (Figure 6). Accordingly, the key to a potent covalent inhib-
itor is the efficient formation of a stable covalent intermediate.
With ara-F-NMN as a model, modifications of the 20 position of
either the arabinosyl ring (Figure 6A) or the ribosyl ring
(Figure 6B) would be the approach. The modifications should
aim to prevent the formation of strong H-bond interactions be-
tween the inhibitors and the catalytic residue. Arabinosyl deriv-
atives would be preferred, as the modified group would be
pointing away from Glu226. The cis-NH2 substitution of the ribo-
syl 20-OH group, however, would not be a good choice, as NH2
can still serve as a hydrogen donor to form H bonds with the cat-
alytic residue.lsevier Ltd All rights reserved
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(A) Covalent inhibitors of 20 substitutions of arabino configuration.
(B) Covalent inhibitors of 20 substitutions of ribose configuration. Among these potential inhibitors, 20 substitution by anNH2 groupmight not be a good covalent
intermediate, as it can likely form an H bond with the catalytic residue Glu226 to stabilize a noncovalent intermediate.
(C) R5P-guanine-based noncovalent inhibitors.As for noncovalent inhibitors, we canmodel after the R5P-GTP
adduct shown in Figure 4C. The electron density of the R5P-GTP
adduct indicates that the R5P and the guanine portion are bound
tightly and have well-defined electron density, while the disor-
dered triphosphate and ribose moieties are not recognized by
the active site. This portion of the adduct can thus be deleted
to make an inhibitor (Figure 6C) that can bind tightly to the active
site and block normal substrates from entering. Candidates of
6-position substititions of the guanine moiety could be a CH2,
NH,O, orS group. One special feature of the inhibitor is that
it possesses very similar stereochemistry to fludarabine phos-
phate, an effective drug for the treatment of chronic lymphocytic
leukemia (Rai et al., 2000). Indeed, studies using knockout mice
have established the importance of CD38 and its enzymatic
activities in a wide range of physiological processes, including
insulin secretion (Kato et al., 1999), a-adrenoceptor signaling in
aorta (Mitsui-Saito et al., 2003), hormonal signaling in pancreatic
acinar cells (Fukushi et al., 2001), migration of dendritic cell pre-
cursors (Partida-Sanchez et al., 2004), bone resorption (Sun
et al., 2003), susceptibility to bacterial infection (Partida-Sanchez
et al., 2001), as well as aberrant social behavior in mice due to
a defect in oxytocin secretion (Jin et al., 2007). The development
of covalent and noncovalent inhibitors for CD38 should thus
have physiological and pharmacological significance in biomed-
ical research of CD38-related diseases in particular, and NAD
metabolism diseases in general.
SIGNIFICANCE
Nicotinamide adenine dinucleotide (NAD) is emerging as an
important regulator for a wide variety of physiological func-Chemistry & Biology 15, 1068–1tions, including signal transduction, gene regulation, and
protein posttranscriptional modification. It can also be
a substrate for the formation of several messenger mole-
cules. The enzymatic reactions of NAD generally involve re-
moval of the nicotinamide moiety and the formation of an
intermediate with the catalyzing enzyme. Both covalent
and noncovalent intermediates have been proposed. In
this study, we have resolved this issue by determining the
structures of both the covalent and noncovalent intermedi-
ates, as well as the Michaelis complexes of CD38. In the co-
valent intermediate, the reaction center, C10, forms a 1.6 A˚
covalent bond with the catalytic residue Glu226. The cova-
lent intermediate is dynamic and can undergo a large rota-
tional movement induced by a nucleophile, nicotinamide.
The covalent intermediate is highly stable, preventing fur-
ther catalysis by CD38. In the noncovalent intermediate,
the reaction center, C10, is 3.5 A˚ from the catalytic residue.
The noncovalent intermediate is stabilized through H bonds
between its ribosyl 20-, 30-OH groups and the catalytic resi-
due, but is much more reactive than the covalent intermedi-
ate. The noncovalent intermediate can be readily attacked
by a nearby nucleophile to form a covalent adduct from the
b face of the intermediate. By comparing the covalent and
noncovalent intermediates, we propose that the determi-
nant for selecting the two distinct intermediate pathways
does not reside in the enzyme itself, but is, rather, the 20 po-
sition of the substrate’s pentose ring. We further propose
that the noncovalent pathway is generally adopted during
reactions involving natural substrates, such as NAD or
NMN. The structural data presented provide clues for de-
signing potent inhibitors for CD38, which should provide078, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1075
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Covalent and Noncovalent Intermediates of CD38Table 1. Crystallographic Data and Refinement Statistics
ara-F-R5P ara-F-R5P/Nic GTP R5PI/GTP NMN/E226Q NMN/wtCD38
Data collection
Cell dimensions
a, b, c (A˚) 41.8, 96.2, 103.6 41.7, 52.8, 65.4 41.7, 52.7, 65.2 41.7, 52.8, 65.1 41.9, 53.3, 65.7 41.9, 53.2, 65.6
a,b,g () 79.5, 82.7, 86.9 106.1, 92.0, 95.1 106.1, 91.8, 95.0 106.1, 91.9, 95.3 106.1, 92.0, 95.1 106.2, 91.8, 95.1
Space group P1 P1 P1 P1 P1 P1
Resolution (A˚) 302.00
(2.072.00)
301.64
(1.701.64)
301.60
(1.661.60)
301.73
(1.791.73)
301.90
(1.981.90)
301.80
(1.861.80)
Unique reflections 90177 61988 65992 53519 41633 47229
Multiplicity 3.6 (3.2) 3.5 (3.0) 3.8 (2.9) 3.6 (2.8) 3.8 (2.9) 3.4 (2.0)
I/s 18.1 (2.5) 17.5 (5.7) 21.6 (2.5) 25.8 (2.0) 21.2 (2.9) 12.6 (1.5)
Rmerge (%)
a 6.4 (48.5) 5.6 (18.9) 5.3 (35.2) 4.2 (45.8) 9.0 (43.6) 9.9 (44.3)
Completeness (%) 86.7 (75.0) 96.3 (86.9) 95.5 (81.6) 95.5 (82.2) 97.5 (95.2) 96.7 (87.2)
Refinement
Resolution (A˚) 202.00 201.65 201.60 201.73 201.90 201.80
R factor (%)b 20.1 17.4 17.6 17.7 18.5 17.3
Rfree factor (%)
c 27.0 21.1 21.8 21.1 24.1 21.7
Protein atoms 12300 4100 4100 4100 4100 4100
Water molecules 770 494 409 399 384 378
Ligands 6 2+2 2 1+1+1 2 2
Mean B (A˚2) 38.8 32.2 29.5 40.1 33.3 33.1
Rmsds
Bond lengths (A˚) 0.022 0.013 0.029 0.016 0.016 0.016
Bond angles () 1.987 1.504 2.475 1.566 1.572 1.523
Values in parentheses are from the highest-resolution shell.
a Rmerge = SjI  < I >j/SI, where I is the integrated intensity of a given reflection.
b R = SjjFobsj  jFcalcjj/SjFobsj.
c Rfree was calculated with 5% of data excluded from refinement.invaluable tools for scientific and diagnostic analysis of the
wide range of physiological functions that are known to be
regulated by CD38.
EXPERIMENTAL PROCEDURES
Synthesis of ara-F-NMN
Reagents were obtained from Aldrich or TCI and were used as supplied. 1H
NMR spectral analysis was carried out at 600 MHz on a Varian Unity INOVA
600. Mass spectra were obtained on a SHIMADZU liquid chromatography
mass spectrometer LCMS-QP8000a. ara-F-NMN was synthesized according
to published procedures (Sleath et al., 1991). 1H NMR (600 MHz, D2O) d were
9.46 (s, 1 H, N2), 9.31 (d, 1 H, N6), 9.01 (d, 1 H, N4), 8.31 (t, 1 H, N5), 6.76 (dd, 1
H, 10), 5.57 (dt, 1 H, 20), 4.64 (dt, 1 H, 30), 4.47 (m, 1 H, 40), 4.36 (m, 1 H, 50 ), and
4.24 (m, 1 H, 500). The m/z value was 336.70 (M+; calculated, 337.06).
Formation of Complexes
Expression, purification, and crystallization of wtCD38 and E226Qmutant pro-
teinswere performedwith procedures as previously described (Liu et al., 2005,
2007; Munshi et al., 2000). GTP, NMN, and nicotinamide were purchased from
SigmaAldrich. The ara-F-R5P complex was obtained by cocrystallization of
wtCD38 with ara-F-NMN. The ara-F-R5P/Nic complex was formed by soaking
wtCD38 crystals in soaking solution containing 15 mM ara-F-NMN, 50 mM
nicotinamide, 100 mM MES, pH 6.0, 15% PEG4000, and 30% glycerol.
The GTP/CD38 complex was formed by soaking wtCD38 crystals with 5mM
GTP, 100 mMMES, pH 6.0, 15%PEG4000, and 30% glycerol for 2 min at 4C.
Trapping of the R5PI intermediate with GTP was done by directly soaking1076 Chemistry & Biology 15, 1068–1078, October 20, 2008 ª2008wtCD38 crystals in 2 ml soaking solution containing 40 mM NMN, 5 mM
GTP, 100mMMES, pH 6.0, 15% PEG4000, and 30% glycerol for 3 min at 4C.
TheNMN/E226Q complexwas formed by incubating E226Qmutant crystals
in 2 ml soaking solution that contained 40 mM NMN, 100 mM MES, pH 6.0,
15% PEG4000, 30% glycerol for 1 min at 0C. The trapping of the NMN/
wtCD38 complex was done by incubating wtCD38 crystals with 2 ml soaking
solution that contained 40 mM NMN, 5 mM guanine, 100 mM MES, pH 6.0,
15%PEG4000, 30% glycerol for 7 min at 4C. The addition of 5mM of guanine
prevented the hydrolysis of NMN to R5P, and was essential for the successful
formation of NMN/wtCD38 complex.
X-ray crystallography
X-ray diffraction data were collected at the Cornell High-Energy Synchrotron
Source A1 station, with crystals protected by a liquid nitrogen cryostream at
100K. For each data set, a total of 360 images with an oscillation angle of 1
were collected from a single crystal using a Quantum Q-210 CCD detector.
All data sets were processed by using the programHKL2000 suite (Otwinowski
and Minor, 1997). The crystallographic statistics are listed in Table 1.
All complex structures were determined by difference Fourier calculation,
with the starting phases derived from the apo wtCD38 model (PDB ID,
1YH3). The models for all ligands were built manually in O (Jones et al.,
1991) based on the sA weighted Fo  Fc difference electron density maps.
For the ara-F-R5P complex, the restraints for covalent linkage between ligands
and catalytic residue Glu226 were loosely restrained at 1.6 A˚; for the ara-F-
R5P/Nic complex, the catalytic residue Glu226 in both molecules was mod-
eled as covalently linked to ara-F-R5P. Two nicotinamide molecules were
modeled near ara-F-R5P ribose; for the GTP complex, the GTP molecule
was modeled in both active sites from both molecules in the crystallographic
asymmetric unit; for the R5PI/GTP complex, an R5P-GTP molecule was builtElsevier Ltd All rights reserved
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Covalent and Noncovalent Intermediates of CD38in the active site of molecule, a trapped R5P intermediate and a GTP molecule
were built in the active site of another molecule; for NMN complexed with
wtCD38 and E226Q mutants, the NMN molecule was built separately for
each case.
Structure refinements for these complexes were performed with the pro-
gram REFMAC (Murshudov et al., 1997) with manually modified stereochem-
ical restraints generated from the program PRODRG (Schuttelkopf and van
Aalten, 2004). TLS group refinements were introduced to model data anisot-
ropy. Solvents were added automatically by Arp/warp andmanually inspected
and modified with the program O. The refinement results and model statistics
are listed in Table 1.
ACCESSION NUMBERS
Atomic coordinates and structure factors have been deposited in the Protein
Data Bank under ID codes 3DZF for ara-F-R5P complex, 3DZG for ara-
F-R5P/Nic complex, 3DZH for GTP complex, 3DZI for R5PI/GTP complex,
3DZJ for NMN/E226Q complex, and 3DZK for NMN/wtCD38 complex.
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